S. Megnien

发表

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science

B. Neuschwander‐Tetri, S. Friedman, V. Miller, 2017, Hepatology.

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Philippe Lehert, Pierre Bedossa, P. Bedossa, 2016, Gastroenterology.

A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.

P. Bedossa, A. Sanyal, D. Hum, 2020, The lancet. Gastroenterology & hepatology.

A Post-Hoc Analysis ofthe Golden505 Trial Demonstrates Histological and Cardiometabolic Efficacy of Elafibranor-120 Mg in Patients with Moderate or Severe Nash That Are Eligible for Pharmacotherapy

P. Bedossa, J. Drenth, A. Sanyal, 2016 .

Improvement in NASH histological activity highly correlates with fibrosis regression

P. Bedossa, A. Sanyal, D. Hum, 2016 .

35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts.

Thomas J. Smith, B. M. Rasmussen, V. C. Phan, 1999, Diabetologia.

Gastrointestinal tolerance to an inulin-rich soluble roasted chicory extract after consumption in healthy subjects.

B. Flourié, C. Ripoll, S. Mégnien, 2010, Nutrition.

CLINICAL — LIVER Ela ﬁ branor, an Agonist of the Peroxisome Proliferator L Activated Receptor L a and L d , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

P. Bedossa, J. Drenth, A. Sanyal, 2022 .

Ela fi branor , an Agonist of the Peroxisome Proliferator L Activated Receptor L a and L d , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

P. Bedossa, J. Drenth, A. Sanyal, 2022 .

A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.

D. Magrez, K. Kowdley, V. Luketic, 2021, Journal of hepatology.

Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.

Claire L. Sampson, V. Miller, D. Kleiner, 2019, Gastroenterology.

Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis

P. Bedossa, A. Sanyal, D. Hum, 2017 .

ALT as a non-invasive biomarker of histological response to pharmacotherapy in NASH patients: insights from the elafibranor GOLDEN505 trial

P. Bedossa, A. Sanyal, D. Hum, 2016 .

LBO-02-Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment

D. Magrez, K. Kowdley, V. Luketic, 2019, Journal of Hepatology.

Gastrointestinal tolerance to an inulin-rich soluble roasted chicory extract after consumption in healthy subjects.

B. Flourié, C. Ripoll, Olivier Hermand, 2010, Nutrition.